April 16, 2021 -- Brooklyn ImmunoTherapeutics has paid $1 million to acquire a license for Factor Bioscience's and Novellus' messenger RNA (mRNA) gene editing and cell therapies technology.
The company is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer. With this deal, Brooklyn extends its option exercise period for entering into a license agreement with Factor Bioscience and Novellus through May 21.
The license would allow Brooklyn to utilize a patented process to seek to develop gene edited compounds using mRNA, which preclinical data suggest to be more efficient, nonimmunogenic, and nonmutagenic, for treatment of several solid tumor and liquid indications such as sickle cell anemia, as well as a number of additional inherited disorders.
The licensed platform would include mRNA cell reprogramming, mRNA-based gene editing, a proprietary gene editing protein, and the proprietary ToRNAdo lipid delivery system that provides delivery of mRNA ex vivo and in vivo to skin, brain, eye, and lung tissue.
Copyright © 2021 scienceboard.net